524 related articles for article (PubMed ID: 31551825)
1. Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders.
Sethi R; Gómez-Coronado N; Walker AJ; Robertson OD; Agustini B; Berk M; Dodd S
Front Psychiatry; 2019; 10():605. PubMed ID: 31551825
[TBL] [Abstract][Full Text] [Related]
2. Inflamed moods: a review of the interactions between inflammation and mood disorders.
Rosenblat JD; Cha DS; Mansur RB; McIntyre RS
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Aug; 53():23-34. PubMed ID: 24468642
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review.
Fond G; Hamdani N; Kapczinski F; Boukouaci W; Drancourt N; Dargel A; Oliveira J; Le Guen E; Marlinge E; Tamouza R; Leboyer M
Acta Psychiatr Scand; 2014 Mar; 129(3):163-79. PubMed ID: 24215721
[TBL] [Abstract][Full Text] [Related]
4. Commentary: Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders.
Westwell-Roper C; Stewart SE
Front Psychiatry; 2020; 11():264. PubMed ID: 32425818
[No Abstract] [Full Text] [Related]
5. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
[TBL] [Abstract][Full Text] [Related]
6. Perfusion magnetic resonance imaging in psychiatry.
Théberge J
Top Magn Reson Imaging; 2008 Apr; 19(2):111-30. PubMed ID: 19363433
[TBL] [Abstract][Full Text] [Related]
7. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications.
Rosenblat JD; Brietzke E; Mansur RB; Maruschak NA; Lee Y; McIntyre RS
J Affect Disord; 2015 Dec; 188():149-59. PubMed ID: 26363613
[TBL] [Abstract][Full Text] [Related]
8. Update on Statin Treatment in Patients with Neuropsychiatric Disorders.
Avan R; Sahebnasagh A; Hashemi J; Monajati M; Faramarzi F; Henney NC; Montecucco F; Jamialahmadi T; Sahebkar A
Life (Basel); 2021 Dec; 11(12):. PubMed ID: 34947895
[TBL] [Abstract][Full Text] [Related]
9. Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis.
Soria V; González-Rodríguez A; Huerta-Ramos E; Usall J; Cobo J; Bioque M; Barbero JD; García-Rizo C; Tost M; Monreal JA; ; Labad J
Psychoneuroendocrinology; 2018 Jul; 93():8-19. PubMed ID: 29680774
[TBL] [Abstract][Full Text] [Related]
10. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial.
Husain MI; Chaudhry IB; Khoso AB; Husain MO; Hodsoll J; Ansari MA; Naqvi HA; Minhas FA; Carvalho AF; Meyer JH; Deakin B; Mulsant BH; Husain N; Young AH
Lancet Psychiatry; 2020 Jun; 7(6):515-527. PubMed ID: 32445690
[TBL] [Abstract][Full Text] [Related]
11. The role of anti-inflammatory treatment in psychiatric disorders.
Müller N
Psychiatr Danub; 2013 Sep; 25(3):292-8. PubMed ID: 24048400
[TBL] [Abstract][Full Text] [Related]
12. The role of macrophage polarization on bipolar disorder: Identifying new therapeutic targets.
Ascoli BM; Géa LP; Colombo R; Barbé-Tuana FM; Kapczinski F; Rosa AR
Aust N Z J Psychiatry; 2016 Jul; 50(7):618-30. PubMed ID: 27091850
[TBL] [Abstract][Full Text] [Related]
13. Anti-Inflammatory Therapy as a Promising Target in Neuropsychiatric Disorders.
Ballaz S; Bourin M
Adv Exp Med Biol; 2023; 1411():459-486. PubMed ID: 36949322
[TBL] [Abstract][Full Text] [Related]
14. Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders.
Müller N; Riedel M; Schwarz MJ
Pharmacopsychiatry; 2004 Nov; 37(6):266-9. PubMed ID: 15551192
[TBL] [Abstract][Full Text] [Related]
15. The genetic architecture of schizophrenia, bipolar disorder, obsessive-compulsive disorder and autism spectrum disorder.
O'Connell KS; McGregor NW; Lochner C; Emsley R; Warnich L
Mol Cell Neurosci; 2018 Apr; 88():300-307. PubMed ID: 29505902
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
Akhondzadeh S; Tabatabaee M; Amini H; Ahmadi Abhari SA; Abbasi SH; Behnam B
Schizophr Res; 2007 Feb; 90(1-3):179-85. PubMed ID: 17208413
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
Müller N; Krause D; Dehning S; Musil R; Schennach-Wolff R; Obermeier M; Möller HJ; Klauss V; Schwarz MJ; Riedel M
Schizophr Res; 2010 Aug; 121(1-3):118-24. PubMed ID: 20570110
[TBL] [Abstract][Full Text] [Related]
18. Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation.
Petra AI; Panagiotidou S; Hatziagelaki E; Stewart JM; Conti P; Theoharides TC
Clin Ther; 2015 May; 37(5):984-95. PubMed ID: 26046241
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
20. Psychiatric comorbidity in persons with high-functioning autism spectrum disorders: Findings from a tertiary care neuropsychiatric hospital.
Nahar A; Thippeswamy H; Shanker Reddy MS; Kishore MT; Chaturvedi SK
Asian J Psychiatr; 2019 Mar; 41():50-53. PubMed ID: 30316630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
